ReviewCurrent atherosclerosis reports2004
Inflammation and atherosclerosis.
Review in Current atherosclerosis reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 61 citations in OpenAlex.
- Lipoic Acid Nanoparticles Exert Effective Antiatherosclerosis Effects through Anti-Inflammatory and Antioxidant Pathways.ACS omega · 2024Article
- Searching for serum biomarkers linking coronary heart disease and Helicobacter pylori infection using infrared spectroscopy and artificial neural networks.Scientific reports · 2022Article
- Role of Lipid-Lowering Therapy in Peripheral Artery Disease.Journal of clinical medicine · 2022Review
- Identification of Differently Expressed mRNAs in Atherosclerosis Reveals CDK6 Is Regulated by circHIPK3/miR-637 Axis and Promotes Cell Growth in Human Vascular Smooth Muscle Cells.Frontiers in genetics · 2021Article
- Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction.International journal of molecular sciences · 2020Review
- Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis.Current pharmaceutical design · 2017Review
- Genetic epidemiology of coronary artery disease: an Asian Indian perspective.Journal of genetics · 2015Review
- Risk factors and biomarkers of ischemic stroke in cancer patients.Journal of stroke · 2014Article
- Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor [corrected] of matrix metalloproteinase-1 in myocardial infarction.The Korean journal of internal medicine · 2013Article
- Article
- Interleukin-4, Oxidative Stress, Vascular Inflammation and Atherosclerosis.Biomolecules & therapeutics · 2010Article
- APOE polymorphism and its effect on plasma C-reactive protein levels in a large general population sample.Human immunology · 2010Article
- Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2009Review
- Pentraxins, anti-pentraxin antibodies, and atherosclerosis.Clinical reviews in allergy & immunology · 2009Review
- Appropriateness of carotid plaque and intima-media thickness assessment in routine clinical practice.Cardiovascular ultrasound · 2008Article
- Adiposopathy is a more rational treatment target for metabolic disease than obesity alone.Current atherosclerosis reports · 2006Review
- -174G>C interleukin-6 gene polymorphism in Tunisian patients with coronary artery disease.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation plays a pivotal role in all stages of atherogenesis, from foam cell to plaque formation to rupture and ultimately to thrombosis. Insight gained from recent basic and clinical data linking inflammation to atherosclerosis has yielded important diagnostic and prognostic information. Low-grade chronic inflammation as measured by high sensitivity C-reactive protein predicts future risk of acute coronary syndrome independent of traditional cardiovascular risk factors. In addition, individuals with higher "inflammatory burden" gain the largest absolute risk reduction with aggressive risk-lowering therapy. The link between inflammation and atherosclerosis provides a new venue for future pharmacologic agents that may slow the progression of atherosclerosis by inhibiting inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.